NCT06073821 2026-04-16
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
11 trialsNCT07277231 2026-04-15
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3 Recruiting
NCT06742996 2026-03-19
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
BeOne Medicines
Phase 3 Recruiting
NCT05100862 2026-03-18
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
NCT03336333 2026-03-09
SEQUOIA
BeOne Medicines
Phase 3 Active not recruiting
NCT07377578 2026-02-06
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 3 Recruiting
NCT04170283 2025-10-21
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
BeOne Medicines
Phase 3 Active not recruiting
NCT04002297 2025-09-26
MANGROVE
BeiGene
Phase 3 Active not recruiting
NCT04662255 2025-05-28
BRUIN-MCL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03734016 2025-03-30
ALPINE
BeiGene
Phase 3 Completed
NCT03053440 2024-10-26
ASPEN
BeiGene
Phase 3 Completed